NCT05453968Phase 3Active not recruiting

Berotralstat Treatment in Children With Hereditary Angioedema

Study sponsor: BioCryst Pharmaceuticals

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-09-11Actual
Enrollment · participants29Actual
Source updated2026-02-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Pharmacokinetics: Cmax Measure: Pharmacokinetics: AUC0-tau Measure: Pharmacokinetics: CL/F. After: Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of Berotralstat Measure: Area Under the Plasma Concentration-Time Curve From Time 0 to 6 Hours Post-dose (AUC0-6) of Berotralstat Measure: Concentration at the End of the Dosing Interval (Ctrough) of Berotralstat Measure: Maximum Observed Plasma Concentration (Cmax) of Berotralstat Measure: Time of Last Measurable Plasma Concentration (Tlast) of Berotralstat Measure: Time to Maximum Plasma Concentration (Tmax) of Berotralstat.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview